Patients and Caregivers

What is CUP and CancerTYPE ID?

As seen on:

Learning that you have cancer can be a challenging and sometimes overwhelming experience. Wanting to know exactly what type of cancer you have is only natural. Sometimes, in advanced cancer that has spread to other parts of the body, or metastasized, your medical team may not be able to tell with certainty where in the body it started off. When this happens, you may be given a diagnosis called Cancer of Unknown Primary, or CUP for short.

A diagnosis of CUP can be confusing and frustrating for patients who want to know what type of cancer they have and understand the treatment options available to them. It is also important for your medical team to try and find out exactly what type of cancer you have as some treatments work better than others in certain types of cancer.

CancerTYPE ID® is a diagnostic test that may help patients with a diagnosis of CUP by providing your medical team with additional information about the type of cancer you have. This information may help your physician design a more personalized treatment plan for your disease.

The test works by comparing genomic information taken from a sample of your tumor to a reference database of over 2,000 tumors that have been clearly diagnosed. It finds the closest match to the different tumor types in the reference database and this information is provided to your physician in a test report.

If you have been told you have Cancer of Unknown Primary or CUP, or if your physician is uncertain of exactly what type of cancer you have, ask how obtaining a molecular diagnosis with CancerTYPE ID may help.

Have questions about the test and/or billing?

CancerType ID Indications for Use and Limitations

CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.